Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Market Closed - Xetra Other stock markets 16:35:27 15/07/2025 BST			After hours 17:43:00
27.32 ^EUR	-0.71%		27.30	-0.04%

07-14	Global markets live: Tesla, Gilead, Kenvue, Amazon, Bayer…
07-14	Bayer Shares Buoyed by US Drug Approval Amid Weak Market	DP

White House 'MAHA' report calls out food, chemicals impact on children's health

Published on 22/05/2025 at 22:42

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Bayer AG

Global markets live: Tesla, Gilead, Kenvue, Amazon, Bayer…	07-14
Bayer Shares Buoyed by US Drug Approval Amid Weak Market	07-14	DP
Bayer's Finerenone Secures New US FDA Indication for Heart Failure Type	07-14	MT
Bayer: Fineronone approved for heart failure in US	07-14
Bayer: new distribution agreement with M2i	07-14
Bayer Expands M2i Group Distribution Deal to Asia-Pacific, Latin America, US	07-14	MT
US FDA Approves Bayer's Heart Failure, Left Ventricular Ejection Fraction Treatment	07-14	MT
Bayer AG announces US FDA approved Kerendia	07-14	RE
Bayer says to expand partnership with M2i Group to distribute pheromone-based biological crop protection solutions globally	07-14	RE
Bayer says U.S. FDA approves finerenone	07-14	RE
BAYER AG : Jefferies reiterates its Neutral rating	07-11	ZD
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	07-11	RE
Bayer Receives U.K. Approval for Hot Flashes Treatment	07-10	DJ
Bayer receives approval for Lynkuet(TM) (Elinzanetant) in UK	07-10	RE
Bayer Rules Out Further Plant Closures in Germany After Frankfurt Exit	07-10	RE
Reaches socially acceptable agreements for the withdrawal from Frankfurt/Main site and secures remaining company sites in Germany until 2030	07-10	RE
Bayer Submits Gadoquatrane for EU Approval to Offer Lower-dose MRI Contrast Agent	07-10	MT
Bayer: application for approval of its contrast agent	07-10
Bayer Seeks EU Approval for Low-Dose MRI Contrast Agent Gadoquatrane	07-10	MT
Bayer files for EU approval of gadoquatrane	07-10	RE
Bayer Wins Maiden Approval For Menopausal Hot Flashes Medication From UK Regulator	07-09	MT
German Equities Jump Amid EU-US Trade Deal Optimism	07-08	MT
MHRA approves elinzanetant to treat moderate to severe vasomotor symptoms caused by menopause	07-08	RE
UK Clears Bayer Medicine for Menopause-related Hot Flashes	07-08	MT
Bayer Treats First Patient in Early-stage Trial for Retinal Disorder Drug Candidate	07-08	MT

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (47.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38.9%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.6%); - other (0.7%). Net sales are distributed geographically as follows: Germany (5.2%), Switzerland (1.2%), Europe/Middle East/Africa (23.6%), the United States (31.7%), North America (3.6%), China (7.7%), Asia/Pacific (9.6%), Brazil (9.3%) and Latin America (8.1%).

Employees

90,885

Sector

Pharmaceuticals

Calendar

08-06 - Q2 2025 Earnings Release

More about the company